

ButyrEn

(Hypoallergenic)



Item # 70220
Available in bottles of 100 tablets

The Possible Benefits of ButyrEn, a Dietary Supplement

- Supports the integrity of the colonic mucosa by supplying a primary fuel for the colonic epithelium
- Supports the maintenance of bifidobacterium in the large intestine
- Helps modulate local electrolyte flux

Description

ButyrEn is an enteric-coated, extended shelf-life formulation of the calcium and magnesium salts of butyric acid, designed specifically for delayed release in the gastrointestinal tract. Butyric acid is a short-chain fatty acid (SCFA) produced by certain probiotic bacteria, and appears to support mucosal integrity. Butyric acid may support the integrity of the colonic mucosa by acting as a primary fuel for the colonic epithelium (colonocytes). Butyric acid (“butyrate” when in salt form) is an important SCFA for this reason.

Colon health is directly related to the metabolic processes occurring in the gut, which itself is directly related to diet. In this way, it can be said that the food we eat, which will in part determine the health of the colon, is a way to communicate with our environment. But how does our food communicate with our environment? It does so because when we take food into our mouths, it begins a process of transformation as it moves through the stomach, then the intestines, and the waste part goes out again into the environment. During this trip, the food becomes changed in structure, or digested. The digested nutrients are free to be absorbed by the circulatory system and delivered to the necessary sites. Upon delivery of the nutrients, the cells receive a message and then the cells create a reaction, the type of reaction depending on the nutrient involved.

Butyrate is created when colonocytes act metabolically on undigested fibre in the colon. This fibre can be considered a prebiotic agent. Prebiotics escape enzymatic digestion in the upper gastrointestinal tract and enter the large intestines unchanged. Instead of being excreted in the stool, these substances are fermented by colonic flora to yield SCFAs such as butyrate. The SCFAs, in turn, will stimulate the bifidobacterium in the large intestine, which may yield health benefits such as boosting the intestinal immune response, producing vitamins and enzymes, producing organic acids that support normal intestinal pH, and supporting the structure and functional integrity of the epithelial lining in numerous ways.

The ability of colonocytes to utilise butyrate can contribute to a healthy condition of the colon or bowel. Butyrate is absorbed by the colonocytes in the proximal colon via passive diffusion and by active transport mechanisms. The mucosal metabolic fluxes of both butyrate and glutamine (a conditionally essential amino acid) have been shown to be connected to several aspects of intestinal health, including healthy intestinal immune response.

Serving Size: 2 Tablets
Servings Per Container: 50

Amount Per Serving:

Calcium (as Calcium Magnesium Butyrate and Calcium Phosphate)	250 mg
Magnesium (as Calcium Magnesium Butyrate and Magnesium Oxide)	200 mg
Butyric Acid (as Calcium Magnesium Butyrate)	200 mg

Other ingredients: Cellulose, povidone, magnesium stearate, silicon dioxide.

Suggested Use: As a dietary supplement, 1 or 2 tablets three times daily with meals, or as directed by a healthcare practitioner.

Note: We previously listed the complete weight of the Butyrate, which includes Butyric Acid, Calcium and Magnesium (a total of 1630 mg per two tablets). We now list the Butyric Acid content separately (200 mg per two tablets). This is a change in labeling only; the actual product has not changed.

Suggested References

Velazquez OC, Lederer HM, Rombeau JL. Butyrate and the colonocyte. Production, absorption, metabolism, and therapeutic implications. Harrison Department of Surgical Research, University of Pennsylvania Medical Center, Philadelphia, 19104, USA.
Stokrova J, Sovova V, Sloncova E, Korb. J Int J Mol Med 1999 Dec;4(6):669-74.
Burke A, Lichtenstein GR, Rombeau JL. Baillieres Clin Gastroenterol 1997 Mar;11(1):153-74.
Duffy MM, Regan MC, Ravichandran P, O'Keane C, Harrington MG, Fitzpatrick JM, O'Connell PR. Dis Colon Rectum 1998 Nov;41(11):1399-405.

Grizard D, Barthomeuf C. Non-digestible oligosaccharides used as prebiotic agents: mode of production and beneficial effects on animal and human health. Reprod Nutr Dev 1999 Sep-Dec;39(5-6):563-88.
Santini V, Gozzini A, Scappini B, Caporale R, Zoccolante A, Rigacci L, Gelardi E, Grossi A, Alterini R, Ferrini PR. HaemOct:84(10):897-904.
Krishnan S, Rajan DP, RGastroenterol 1998 Mar atologica
1999 amakrishna BS. Scand J ;33(3):242-6.